EP2983591A4 - PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY - Google Patents

PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY

Info

Publication number
EP2983591A4
EP2983591A4 EP14783066.5A EP14783066A EP2983591A4 EP 2983591 A4 EP2983591 A4 EP 2983591A4 EP 14783066 A EP14783066 A EP 14783066A EP 2983591 A4 EP2983591 A4 EP 2983591A4
Authority
EP
European Patent Office
Prior art keywords
biomarker
prediction
response
anticancer therapy
anticancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP14783066.5A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2983591A1 (en
Inventor
Charles Hart
Harold E Selick
Jessica Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Templates Inc
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of EP2983591A1 publication Critical patent/EP2983591A1/en
Publication of EP2983591A4 publication Critical patent/EP2983591A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A61B6/02—Arrangements for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
    • A61B6/03—Computed tomography [CT]
    • A61B6/037—Emission tomography

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP14783066.5A 2013-04-10 2014-04-09 PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY Withdrawn EP2983591A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361810643P 2013-04-10 2013-04-10
PCT/US2014/033491 WO2014169035A1 (en) 2013-04-10 2014-04-09 Predictive and response biomarker for th-302 anti-cancer therapy

Publications (2)

Publication Number Publication Date
EP2983591A1 EP2983591A1 (en) 2016-02-17
EP2983591A4 true EP2983591A4 (en) 2016-12-28

Family

ID=51689977

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14783066.5A Withdrawn EP2983591A4 (en) 2013-04-10 2014-04-09 PREDICTIVE AND RESPONSE BIOMARKERS FOR TH-302 CANCER THERAPY

Country Status (4)

Country Link
US (1) US20160296538A1 (enExample)
EP (1) EP2983591A4 (enExample)
JP (1) JP2016519107A (enExample)
WO (1) WO2014169035A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071109B2 (en) 2013-11-06 2018-09-11 Molecular Templates, Inc. Predictive biomarker for hypoxia-activated prodrug therapy
CN107427515B (zh) 2014-12-03 2021-11-16 奥克兰联合服务有限公司 用于治疗癌症的激酶抑制剂前药
US11504075B2 (en) * 2017-12-20 2022-11-22 University Health Network System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging
WO2023025291A1 (zh) 2021-08-27 2023-03-02 深圳艾欣达伟医药科技有限公司 冻干制剂溶液及冻干制剂、方法和用途
JP7762796B2 (ja) 2021-08-27 2025-10-30 アセンタウィッツ ファーマシューティカルズ リミテッド Ｐａｒｐ阻害剤に耐性のある患者のｔｈ－３０２による治療
US20250186468A1 (en) 2022-03-15 2025-06-12 Ascentawits Pharmaceuticals, Ltd. Method for treating patient with brca-mutated cancer
EP4509127A4 (en) 2022-04-15 2026-07-15 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD USING TH-302 ALONE OR IN COMBINATION WITH A PARP INHIBITOR
EP4529926A4 (en) 2022-05-23 2026-07-01 Ascentawits Pharmaceuticals Ltd CANCER TREATMENT METHOD BY COMBINATION OF AN ALKYLATING AGENT PRODRUGATION AND A CELL CYCLE INHIBITOR
CN119894521A (zh) 2022-09-22 2025-04-25 深圳艾欣达伟医药科技有限公司 乏氧激活的化合物在制备治疗癌症患者的药物中的用途
EP4674418A1 (en) 2023-02-27 2026-01-07 Ascentawits Pharmaceuticals, Ltd. Solution, freeze-dried formulation, freeze-dried formulation unit package, injection, and injection preparation method
EP4755396A1 (en) 2023-07-28 2026-06-10 Ascentawits Pharmaceuticals, Ltd. Treatment of p53 gene mutation or defect negative cancer and tumor patients
CN121985960A (zh) 2023-10-18 2026-05-05 深圳艾欣达伟医药科技有限公司 治疗p53基因突变阴性、kras基因突变阳性、brca突变阳性患者

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2012008860A2 (en) * 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20070117784A1 (en) * 2005-03-04 2007-05-24 Novacea, Inc. Treatment of hyperproliferative diseases with anthraquinones
WO2010048330A1 (en) * 2008-10-21 2010-04-29 Threshold Pharmaceuticals, Inc. Treatment of cancer using hypoxia activated prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012006032A2 (en) * 2010-06-28 2012-01-12 Threshold Pharmaceuticals, Inc. Treatment of blood cancer
WO2012009288A2 (en) * 2010-07-12 2012-01-19 Threshold Pharmaceuticals, Inc. Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
WO2012008860A2 (en) * 2010-07-16 2012-01-19 Auckland Uniservices Limited Bacterial nitroreductase enzymes and methods relating thereto

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. HU ET AL: "Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug", BLOOD, vol. 116, no. 9, 2 September 2010 (2010-09-02), US, pages 1524 - 1527, XP055321592, ISSN: 0006-4971, DOI: 10.1182/blood-2010-02-269126 *
QIAN LIU ET AL: "TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 69, no. 6, 2 March 2012 (2012-03-02), pages 1487 - 1498, XP035062681, ISSN: 1432-0843, DOI: 10.1007/S00280-012-1852-8 *
See also references of WO2014169035A1 *

Also Published As

Publication number Publication date
US20160296538A1 (en) 2016-10-13
JP2016519107A (ja) 2016-06-30
EP2983591A1 (en) 2016-02-17
WO2014169035A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
HUE057061T2 (hu) Kombinációs terápia rák kezelésére
EP4274558A4 (en) Combination therapy for neuroendocrine tumors
DK3036329T3 (da) Immunonkolytiske terapier
EP2968010A4 (en) PERSONALIZED AUDITORIC SOMATOSENSORY STIMULATION FOR TINNITUS TREATMENT
CL2015001049A1 (es) Terapia de combinación de anticuerpos anti-her3
EP2931922A4 (en) PERSONALIZED BIOMARKERS FOR CANCER
EP2968542A4 (en) BIOMARKERS FOR RADIATION TREATMENT
EP2973806A4 (en) PROTECTION STRUCTURES FOR ELECTRODES
FR2996267B1 (fr) Appareil hydraulique presentant une structure amelioree pour sa mise en cylindree
EP2810076A4 (en) PRÄDIKTIVER BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUGTHERAPY
DK3019185T3 (da) Kombinationsbehandling for atopisk dermatitis
LT3563837T (lt) Terapija bakteriofagu
DK3004875T3 (da) Prædiktiv biomarkør til cancerterapi
IL240499B (en) Caix stratification based cancer treatment
EP2954947A4 (en) Impeller mixer for electrode slurry
EP2973178A4 (en) INCREASED SAFETY FOR A HARDWARE DECODER
IL244632A0 (en) Cancer biomarker and diagnostic
EP2986978A4 (en) MINIGELKAMM
EP2957677A4 (en) LID FOR UNDERGROUND CONSTRUCTION
FR3003233B1 (fr) Panneau de voilure pour aeronef
FR3013944B1 (fr) Installation pour le gavage de palmipedes
GB201306394D0 (en) Cancer biomarker
EP3060917A4 (en) ASSAYS FOR MACROMOLECULAR ANALYTES
FR3007683B1 (fr) Tribofinition pour plaquette
FR3014968B1 (fr) Insert filete pour panneau sandwich

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151106

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20161129

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/675 20060101ALI20161123BHEP

Ipc: A61K 49/00 20060101ALI20161123BHEP

Ipc: A61B 6/03 20060101AFI20161123BHEP

Ipc: A61K 51/04 20060101ALI20161123BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180925